Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
about
A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathyTopography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational diseaseInteractions causing the kinetic trap in serpin protein foldingHigh-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: A new tool for detailed interaction studies and modelingStructural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.Pleiotropic functions of plasminogen activator inhibitor-1.The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavageChemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.The many faces of protease-protein inhibitor interactionRole of Lys335 in the metastability and function of inhibitory serpins.Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environmentMaspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.Plasminogen activator inhibitor-1 does not contribute to the pulmonary pathology induced by acute exposure to ozone.Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular DiseaseExtending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.The status of plasminogen activator inhibitor-1 as a therapeutic target.The biostructural pathology of the serpins: critical function of sheet opening mechanism.A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibitionA structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.Retarded protein folding of deficient human alpha 1-antitrypsin D256V and L41P variants.Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.Small Molecule Targeting of PAI-1 Function: A New Therapeutic Approach for Treatment of Vascular StenosisMetals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization.The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity.Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator.Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.Significance of secondary structure predictions on the reactive center loop region of serpins: a model for the folding of serpins into a metastable state.Characterization of a human alpha1-antitrypsin variant that is as stable as ovalbumin.Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms.A Kinetic Mechanism for the Polymerization of α1-Antitrypsin
P2860
Q24564566-C16C0473-3F08-4E21-9DC0-D618D2526CDCQ27626230-ADBB4EF4-B234-4582-ACD4-65CF11AB3D87Q27639675-BE497E40-7EAF-4C05-A1FE-A6C7D495A673Q27651791-67AAE816-E269-4F98-BD0E-128A4103CE56Q27666429-3B7DC417-8E90-4AD5-A9F3-D38216A44E58Q30502082-A0E5E79E-8A46-4396-A768-9D1BBF15C801Q33984228-65322D05-E0F1-438D-A642-5AEDF976F431Q34584787-757E32EC-A3ED-4678-AEE3-4923DD6DFDB7Q35181410-A01EF925-5E76-4258-AEE4-71D129299F7AQ35764595-BFCB3408-CA02-4D54-A244-CD70A4247D2CQ36073813-4CF1D410-53C8-43EF-B933-4B3D67A58C3FQ36282050-FC25A307-D144-44C3-9D82-18F6C348BA55Q36639269-03C7D595-277F-4567-ABD4-B0E71F40DD59Q37264167-B4CAE4F5-922F-4A77-A2B5-73E6E93DA85FQ37286847-FF1261A4-B4F0-49B9-92BC-68A82B6B9881Q38128321-C4981EFC-CD74-4B72-930F-E7423C4AD721Q38271704-02CE9CA0-B36D-428F-8DDD-D0E3912B5DF2Q40243697-AC8E3ED7-C803-42F6-A945-35C0B9029CCCQ40325503-07C2D754-B499-44BF-8855-2FF3C08D82CFQ40894566-396757F8-B8C1-4E63-8CD5-CA5694FAEFF6Q41224616-53BAEB00-E1EF-44CD-8C08-E033EC3D605FQ41412986-1A37CC03-97BA-4D7B-B323-6B66DDD0AFC3Q41790954-9959FEAA-94F7-4D3F-8DE1-4987FB6CD589Q41823150-2D096BF5-AAE3-4DF3-B679-34853312EEF9Q42126974-66451C63-1EB6-4FDD-BC21-9E55552DA496Q42151510-99603D40-864C-4141-8CFB-8C3C1E5F0606Q42158629-3CC34F58-A70D-4B89-89DC-2686C2DBF50EQ42649852-DF6FA443-E990-4169-B442-D407D22E4898Q42994860-0570E796-5993-4C87-9F16-55FAEEDC2BE4Q43559468-367819AF-0A93-477F-8C82-5E01B6B980BCQ43739493-38B22C2E-6C00-491D-900E-FC4443392048Q43815493-9C8C8766-AD31-418A-81C4-1A610536CC2EQ44807445-BE08202E-6C02-4EF9-BD73-F631368D5E38Q46584036-0192B77C-A1FD-44EB-ADEE-2FB140820CFCQ48065485-822A7AD6-7B1E-421C-AED2-BEA73F544E1CQ53959131-BC599B1E-C4DF-4C11-97B0-DACF4BC42EC4Q54038662-F244B03E-E623-478F-AC82-EE3A6CA7C7AFQ54157402-3C561F05-A71A-4C88-9136-E4B21BE39B60Q57980265-AAC08B17-E7AB-43BC-A037-A8B167979E2A
P2860
Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@ast
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@en
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@nl
type
label
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@ast
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@en
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@nl
prefLabel
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@ast
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@en
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@nl
P2093
P2860
P3181
P356
P1476
Mechanisms contributing to the ...... sminogen activator inhibitor-1
@en
P2093
Aertgeerts K
De Bondt HL
De Ranter CJ
P2860
P304
P3181
P356
10.1038/NSB1095-891
P577
1995-10-01T00:00:00Z